Studying the Effects of Classic Hallucinogens in the Treatment of Alcoholism: Rationale, Methodology, and Current Research with Psilocybin
Current Drug Abuse Reviews – June 01, 2013
Source: OpenAlex
Summary
Classic hallucinogens like psilocybin and lysergic acid diethylamide (LSD) show renewed promise for addiction treatment. A compelling finding is the re-evaluation of older literature, alongside new insights from Psychedelics and Drug Studies, highlighting their therapeutic potential. This involves understanding their Neurotransmitter Receptor Influence on Behavior, stemming from their unique chemical synthesis and alkaloids. Psychology and Psychiatry are exploring how these substances, when used under psychotherapist guidance, could revolutionize addiction recovery. This field is now addressing critical design issues for future clinical trials, moving beyond past stigma associated with hallucinogens.
Abstract
Recent developments in the study of classic hallucinogens, combined with a re-appraisal of the older literature, have led to a renewal of interest in possible therapeutic applications for these drugs, notably their application in the treatment of addictions. This article will first provide a brief review of the research literature providing direct and indirect support for the possible therapeutic effects of classic hallucinogens such as psilocybin and lysergic acid diethylamide (LSD) in the treatment of addictions. Having provided a rationale for clinical investigation in this area, we discuss design issues in clinical trials using classic hallucinogens, some of which are unique to this class of drug. We then discuss the current status of this field of research and design considerations in future randomized trials.